Somatostatin and its receptors (SSTR1 to SSTR5) are expressed in normal human parafollicular C cells and medullary thyroid carcinoma (MTC), but the role of SSTR subtypes in cell growth regulation is still not clear. The present study demonstrates that the human MTC cell line TT stably expresses all the SSTR subtypes and responds to SSTR2 and SSTR5 activation by subtype-selective agonists with two different patterns in terms of [ 
S OMATOSTATIN (SRIF) EXERTS its diverse physiolog-
ical actions by interacting with a family of G proteincoupled membrane receptors. Five distinct receptor subtypes, variably expressed in normal and neoplastic cells, have been characterized so far (1) (2) (3) .
SRIF and various analogs have been shown to inhibit normal and neoplastic cell proliferation in vitro and in vivo (2) via specific SRIF receptors (SSTRs) (3) and possibly different postreceptor actions (4, 5) . In addition, there is evidence that distinct SSTR subtypes are expressed in normal and neoplastic human tissues (6) , conferring different tissue affinities for various SRIF analogs and variable clinical response to their therapeutic effects.
Medullary thyroid carcinoma (MTC) is a tumor originating from thyroid parafollicular C cells that produce calcitonin (CT) as well as several other peptides, including SRIF (7) . Recently, Mato et al. (8) showed that SRIF and SSTRs are expressed in human MTC. It has been documented that SRIF and its analogs induce a decrease in plasma CT levels and a symptomatic improvement in MTC patients. However, the antiproliferative activity of SRIF analogs on tumor cells is still controversial (9 -11) and the specific role of SSTR subtypes in cell growth regulation is currently under investigation. In this respect, development and assessment of SSTR subtype analogs selective on MTC cell growth may provide insight for clinical application.
In this study, we tested the effects of SSTR2 and SSTR5 agonists and of a SSTR2 antagonist on cell proliferation with a human MTC cell line, TT (12) , characterized by the presence of a mutation involving exon 11 of the Ret proto-oncogene (13) . Availability of these new SSTR subtype-selective agonists allowed us to gain insight into the individual functions of two SSTR subtypes, SSTR2 and SSTR5, in modulating the tumoral proliferation of parafollicular C cells. These observations may facilitate the rational development of novel drugs that more selectively interact with SSTR2 as a potential treatment for MTC.
Materials and Methods

TT cell line culture
The TT cell line was obtained from the American Type Culture Collection (Manassas, VA). This cell line, established from a specimen obtained by needle biopsy from a 77-yr-old female with MTC (12) , consists of aneuploid transformed CT-producing parafollicular cells that are characterized by the presence of a TGC to TGG mutation (Cys to Trp) at exon 11 codon 634 in the Ret proto-oncogene (13) , a characteristic that we confirmed in the cell line we worked with (data not shown). Moreover, TT cells display an impaired expression of the tumor suppressor gene p53 (14) . Immunohistochemistry studies demonstrated that TT cells express CT and CT receptor (15), carcino-embrionic antigen, SRIF, neurotensin, gastrin-releasing peptide, Leu-and Met-enkephalin, paratormone-releasing peptide, chromogranin A, SP-I, synaptophysin, neuron-specific enolase, 1,25-dihydroxyvitamin d 3 receptor, thyrosin hydroxylase, ␣-tubulin, and cytocheratin (16) . TT cells secrete a significant amount of CT and respond to changes in ionized calcium levels (17) . Therefore, this cell line seems suitable for studies on parafollicular cell function and responses to endocrine and pharmacological stimuli.
Cells were maintained in Ham's Nutrient Mixture F12 with glutamine (EuroClone Ltd, Torquay, UK), supplemented with 10% FBS (Life Technologies, Inc., Milano, Italy), 100 U/mL penicillin, 0.1 mg/mL streptomycin, and 100 g/mL amphotericin (EuroClone Ltd) at 37 C in a humidified atmosphere of 5% CO 2 and 95% air.
Isolation of RNA and RT-PCR
Total RNA was extracted from subconfluent TT cells by using TRIzol (Life Technologies, Inc.), according to the manufacturer's protocol. To prevent DNA contamination, RNA was treated with ribonuclease-free deoxyribonuclease (Promega Corp., Milano, Italy).
Using a first strand complementary DNA (cDNA) synthesis kit (SuperScript Preamplification System for First Strand cDNA Synthesis; Life Technologies, Inc.), 1 g total RNA was reverse transcribed with random hexamers according to the manufacturer's protocol. RT reaction was carried out in the Minicycler (MJ Research, Inc., Watertown, MA) as described previously (18) . The cDNA (1 L RT reaction) was then amplified by PCR with 1 U Taq DNA polymerase (Life Technologies, Inc.) in the conditions recommended by suppliers. PCRs were carried on using the oligonucleotide primers and the conditions listed in Table 1 , describing the size of expected fragments. PCR products were analyzed on a 2% agarose gel and visualized by ethidium bromide staining. To assure that no contamination occurred during the course of the RT-PCR procedure, two kinds of negative control were prepared. The first negative control was made by omitting the total RNA in the RT. The second was prepared by replacing the cDNA mix with water in the PCR. The PCR was considered useful only if no band was observed in the negative control lanes on a 2% agarose gel. Each PCR product was subjected to restriction enzyme digestion and analyzed on 2% agarose gel to further confirm the correct identification of the amplicons (data not shown).
SSTR-selective agonists and antagonists
The SRIF analogs used in this study and their respective affinities to the different SSTRs are listed in Table 2 . Each compound, provided by Biomeasure Inc. (Milford, MA), was resuspended in 0.01 n acetic acid containing 0.1% BSA, to provide uniform solubility and prevent nonspecific binding to the various preparation surfaces. Specificity and selectivity of the analogs were determined by radioligand binding assay on Chinese hamster ovary (CHO)-K1 cells stably transfected with each of the SSTR subtypes, as described previously (19) .
Biological activity evaluation
Biological activity of SSTR-selective agonists and antagonists was evaluated by the calcium mobilization assay (20) in CHO-K1 cells, expressing the human SSTR2 or SSTR5. The cells were harvested by incubating in a 0.3% EDTA/PBS solution (25 C), and washed twice by centrifugation. The washed cells were resuspended in HBSS for loading of the fluorescent Ca 2ϩ indicator fura-2AM. Cell suspensions (approximately 100 cells/ml) were incubated with 2 mm fura-2AM for 30 min at 25 C. Unloaded fura-2AM was removed by centrifugation twice in HBSS, and the final suspensions were transferred to a spectrofluorometer (Hitachi F-2000, Salem, NH) equipped with a magnetic stirring mechanism and a temperature-regulated cuvette holder. After equilibration to 37 C, the SRIF analogs were added for measurement of intracellular Ca 2ϩ mobilization. The excitation and emission wavelengths were 340 and 510 nm, respectively. In the SSTR2-expressing cells (Fig. 1) , BIM-23120 and BIM-23014 have been shown to stimulate intracellular Ca 2ϩ mobilization (indicated as the ratio between stimulated and basal value), whereas no effect has been observed with BIM-23627. In addition, BIM-23197 and BIM-23190 were also highly potent in stimulating Ca 2ϩ mobilization (data not shown). In the SSTR5-expressing cells (Fig. 2) , BIM-23206 and BIM-23014 have been shown to stimulate intracellular Ca 2ϩ mobilization, whereas BIM-23627 displayed slight agonist activity in the range of 300-1000 nm. In the SSTR2-expressing cells (Fig. 3) , BIM-23627 inhibited SRIFinduced intracellular Ca 2ϩ mobilization in a dose-dependent manner with complete suppression of SRIF action at 10 Ϫ7 m. Therefore, the evaluation of intracellular Ca 2ϩ mobilization demonstrated that the biological activity of the various analogs was in keeping with their receptor binding profile.
DNA synthesis
The effects of SSTR-selective agonists and antagonists on TT cell DNA synthesis were assessed by determining the rate of [ 3 H]thymidine ([ 3 H]thy) incorporation, as described previously (21) . TT cells were plated in 24-multiwell plates (10 5 cells/well) and incubated for 48 h in a medium supplemented with 10% FBS in the presence of [ 3 H]thy (1.5 Ci/mL; 87 Ci/mmol) with or without each SRIF analog at concentrations ranging from 10 Ϫ6 to 10 Ϫ9 m. Treatments were renewed after the first 24 h of incubation. After incubation, cell-associated radioactivity was counted in a scintillation spectrometer. Results (cpm per well) were obtained by determining the mean value of at least 6 experiments in quadruplicate. The viability of TT cells in control and treated cultures was evaluated by trypan blue staining after 24 and 48 h, and the number of viable cells was always 85-95%.
Cell proliferation
The effects of SSTR-selective agonists and antagonists on TT cell proliferation were assessed by the CellTiter 96 Aq ueous NonRadioactive Cell Proliferation Assay (Promega Corp.), a colorimetric method for determining the number of viable cells in proliferation assays (22) . Briefly, TT cells were plated in 96-multiwell plates (2 ϫ 10 4 cells/well) and incubated for 48 h in a medium supplemented with 10% FBS in the presence or absence of each SRIF analog at concentrations ranging from 10 Ϫ6 to 10 Ϫ9 m. Treatments were renewed after the first 24 h of incubation. At the end of the incubation period, the plates were incubated for an additional 4 h at 37 C in a humidified 5% CO 2 atmosphere with the staining solution. The absorbance at 490 nm was then recorded using an enzyme-linked immunosorbent assay plate reader (EASIA Reader; Medgenix, Camarillo, CA). Results (absorbance at 490 nm) were obtained by determining the mean value of at least 6 experiments in 8 replicates.
Statistical analysis
All values are expressed as the mean Ϯ se. A preliminary analysis was carried out to determine whether the data sets conformed to a normal distribution, and a computation of homogeneity of variance was performed using Bartlett's test. The results were compared within each group and between groups using ANOVA. If the F values were signif- icant (P Ͻ 0.05), Student's paired or unpaired t test was used to evaluate individual differences between means.
Results
SSTR expression in the human MTC cell line TT
To understand the individual role of SSTR2 and SSTR5 subtypes in controlling parafollicular C cell proliferation, we evaluated whether TT cells express SSTRs that could mediate a potential response to selective compounds for individual SSTR subtypes. To address this question, we isolated total RNA from cultured TT cells and performed RT-PCR in the conditions described in Materials and Methods. Integrity of cDNA was assured by the presence of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) signal. Positive amplification of SSTR1, 2, 3, 4, and 5 was found in the examined cell line (Fig. 4) , demonstrating that these receptors are expressed in human MTC cell line TT.
The demonstration that TT cell line stably expresses SSTR subtypes made this cellular model system suitable for evaluating the action of receptor-selective SRIF analogs. 
Effect
Effect of selective SRIF analogs on TT cell proliferation
To examine in more detail the activity of SRIF analogs on TT cell growth, their effect on viable cell number was also analyzed. The effects of SSTR2 preferential agonists (BIM-23120, BIM-23197, BIM-23190, and BIM-23014), SSTR5 preferential agonist (BIM-23206) and SSTR2 preferential antagonist (BIM-23627) on viable TT cell number at concentrations ranging from 10 Ϫ9 to 10 Ϫ6 m are represented in Fig. 6 . As indicated, all SSTR2 preferential compounds significantly inhibited cell proliferation when compared with untreated control cells at each concentration tested. The selective SSTR5 agonist, BIM-23206, produced a slight increase of TT cell proliferation (up to 11% at 10 Ϫ8 m), without reaching statistical difference from the untreated control cells. The selective SSTR2 antagonist, BIM-23627, did not affect TT cell growth, regardless of the concentration used.
Selective SSTR2 antagonist BIM-23627 counteracts the effects of SSTR2-preferential agonists BIM-23014 and BIM-23120
To further clarify whether SSTR2 is specifically involved in mediating the antiproliferative activity of the two SSTR2 preferential agonists, BIM-23120 and BIM-23014, [ 3 H]thy incorporation and cell growth were evaluated in TT cells exposed for 48 h to each compound either alone (at 10 Ϫ7 m) or in combination with BIM-23627, a selective SSTR2 antagonist, at equimolar concentration (10 Ϫ7 m). The inhibition of [ 3 H]thy incorporation induced by both BIM-23120 and BIM-23014 was totally suppressed by cotreatment of TT cells with BIM-23627 (Fig. 7, top) . TT cell proliferation inhibition induced by BIM-23014 was significantly reduced from 46% to 10%, by cotreatment with BIM-23627. BIM-23627 totally blocked the antiproliferative activity of BIM-23120 (Fig. 7,   FIG. 4 . SSTR mRNA expression in TT cells. Extracted RNA (1 g/reaction) was treated with deoxyribonuclease and subjected to RT. Aliquots from the generated cDNA were subjected to subsequent PCR amplification of SSTRs, using the primers indicated in Table 1 . PCR products were resolved on a 2% agarose gel. The expected PCR products of SSTR1-5 are indicated with arrows (lane M, PCR marker; lane G, PCR product of GAPDH amplification). bottom). Thus, the specific involvement of SSTR2 in mediating the inhibitory effect of BIM-23120 and BIM-23014 on TT cell proliferation is further substantiated.
Effect of combination of preferential SSTR2 agonist, BIM-23120, with preferential SSTR5 agonist, BIM-23206, on [ 3 H]thy incorporation and cell proliferation
The finding that the highly selective SSTR5 agonist, BIM-23206, significantly increased (Fig. 8, top) and proliferation (Fig. 8,  bottom) produced by BIM-23120 (10 Ϫ7 m). These data indicate an antagonism between SSTR5 and SSTR2 preferential compounds. This may imply a complex interplay between SSTR2 and SSTR5 in the control of cell proliferation in the human TT cell line with negative and positive regulatory roles, respectively.
Discussion
The discovery of five distinct SSTR subtypes and their differential expression in human tissues (for review, see Ref.
3) has stimulated research toward developing SRIF analogs with high selectivity for SSTR subtypes to provide new therapeutic strategies based upon different biological roles and tissue-and tumor-specific SSTR subtype expression.
In this study, RT-PCR analysis provided evidence that all five SSTR subtype messenger RNAs (mRNAs) are expressed in a human MTC cell line, TT, which displays all MTC cell characteristics (20, 23, 24) . Recent studies have shown that the MTT cell line, a human-medullary carcinoma cell line variant derived from the TT cell line (14) , expresses SSTR2, 3, 4, and 5 mRNAs, but not SSTR1 mRNA (25) . The reason for the discrepancy between our findings and those of Medina et al. (25) is unclear. However, our detection of SSTR1 mRNA expression in TT cell line is an agreement with recent data of Mato et al. (8) , showing that SSTR1, 2, 3, and 5 subtype mRNAs are detectable by RT-PCR in a series of human MTC, with predominant expression of SSTR2 and 5 subtypes. Normal human thyroid seems to predominantly express SSTR3 and 5, whereas follicular carcinoma cell lines display a different expression pattern, being SSTR1 and 3 the most represented (26). There is increasing evidence that SRIF regulates cell proliferation either arresting cell growth via SSTR1, 2, 4, and 5 subtypes (27) (28) (29) (30) or inducing apoptosis via SSTR3 subtype (31) . Until now, data concerning specific SSTR subtype involvement in MTC cell growth regulation have not been reported. In this study, we tested the ability of SRIF analogs with differing affinity and specificity for SSTR2 and 5 subtypes to influence TT cell growth, evaluating proliferative activity by means of number of viable cells and [
3 H]thy incorporation, which is considered an indirect measure of DNA synthetic activity.
All SSTR2 preferential agonists were able to significantly suppress TT cell number at concentrations ranging from 10 Ϫ7 m was not associated with any cytotoxic action, as demonstrated by trypan blue staining. Moreover, this effect was completely counteracted by cotreatment of TT cells with BIM-23627, a selective SSTR2 antagonist. Taken together, these results indicate that SRIF analogs BIM-23120 and BIM-23014 with preferential selectivity for SSTR2 inhibit TT cell proliferation specifically by interacting with SSTR2. Therefore, our findings support an inhibitory role for SSTR2 in regulating cell proliferation, as reported previously (4) . Understanding the differential effects on both DNA synthesis and cell division of different SRIF analogs displaying relative selectivity for SSTR2 may be important in developing new compounds with specific antiproliferative activity.
Remarkably, we have shown that BIM-23206, a compound discovered to have a high affinity and specificity for SSTR5, unexpectedly induced TT cell [ 3 H]thy incorporation but did not influence cell number, providing evidence that selective activation of SSTR5 in TT cell line promotes DNA synthesis with no effect on cell proliferation. These results prompted us to combine the selective SSTR5 agonist, BIM-23206, together with the highly selective SSTR2 agonist, BIM-23120, which displays similar monospecificity for SSTR2 subtype. Combination of these compounds resulted in an attenuation of the selective effects exerted on both [ 3 H]thy incorporation and cell number by either agonist alone. Moreover, the preferential SSTR5 analog BIM-23206 completely counteracted the suppressive activity of BIM-23120 alone on [ 3 H]thy incorporation and cell proliferation.
Taken together, these data show that TT cell line proliferative activity can be reduced by SSTR2-selective agonists, but not by a SSTR5 agonist, and that an SSTR5 agonist can prevent SSTR2-mediated antiproliferative effects. This evidence suggests that SSTR2 and 5 promote different effects on TT cell growth, and demonstrate that interaction and balance between distinct SSTRs can influence cell growth rate. However, the finding that SSTR5 activation reduces the antiproliferative activity mediated by SSTR2 differs from results in other tissues (4, 27, 28, 31) and may suggest tissue-specific differences in the function of SSTR subtypes 2 and 5. The human TT cell line is characterized by the loss of expression of the tumor suppressor gene p53 and a genetic mutation involving exon 11 of the Ret proto-oncogene (14) . It cannot be excluded that alterations in cell cycle regulatory pathways in TT cells may be responsible for the unexpected actions exerted by SSTR5 on cell growth regulation. However, additional studies need to be considered to clarify this point. Furthermore, to investigate the effects of different SRIF analogs on TT cell proliferation, it could be of considerable interest to study their action on TT cell xenograft tumors in nude mice.
Hetero and homodimeric interactions between subtypes of the opiate (32) and SRIF (33) receptor families have also been recently demonstrated by other investigators. Interestingly, studies in cultured pituitary adenoma cells have demonstrated that SSTR subtypes 2 and 5 act synergistically in the suppression of GH and PRL secretion (34, 35) . To our knowledge, this is the first demonstration that SSTR subytpe 2 and 5, can act antagonistically in regulating cell growth. These findings suggest not only tissue-specific functions, but also tissue-specific interactions between the two receptors. Such diverse interactions between receptor subtypes may prove to be one of the mechanisms by which a seemingly ubiquitous hormone such as SRIF with widespread receptor distribution can achieve functional selectivity in different tissues and physiological states. Clearly, this is an area requiring and deserving much additional study.
In conclusion, our data show that SSTR2 and 5 preferential agonists exert differential effects on proliferation of human medullary thyroid TT cell line in vitro, according to their specific SSTR selectivity. Furthermore, in these cells, we have provided the first demonstration of an antagonistic functional interaction between two SSTR subtypes. The study provides strong evidence for a key inhibitory role of SSTR2 on MTC cell proliferation, at least in TT cellular model system. This finding demonstrates the potential that analogs with enhanced SSTR2 affinity and selectivity may have as antiproliferative agents in MTC treatment.
